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1  | INTRODUC TION
Endometriosis is an enigmatic gynaecological disease characterized 
by ectopic implantation of endometrial like tissues in extra-uterine 
sites.1 It afflicts approximately 10% of reproductive-aged women, 
2%-11% of asymptomatic women, and almost half of the women 
experiencing chronic pelvic pain and associated with dysmenor-
rhoea, dyspareunia, pelvic pain and infertility.1,2 The pathogenesis of 
endometriosis is not precisely understood.3 Among numerous the-
ories proposed to elucidate the pathophysiology of endometriosis, 
peritoneal implantation of viable endometrial cells during retrograde 
menstruation is the generally accepted one.4 However, retrograde 
menstruation occurs in almost all reproductive-aged women, but 
only 10%-20% of them develop endometriosis, so other factors 
must be involved in implantation and survival of the displaced en-
dometrial cells.5 Based on recent findings, immune dysregulation 
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Abstract
Endometriosis is an inflammatory disease affecting reproductive-aged women. 
Immunologic disturbance, as well as inflammation, have crucial roles in the pathogen-
esis of endometriosis. In this study, we evaluated the effects of resveratrol treatment 
on expression of monocyte chemotactic protein-1 (MCP-1), interleukin-6 (IL-6), IL-8, 
and regulated upon activation, normal T cell expressed and secreted (RANTES) in en-
dometrial stromal cells from patients with endometriosis compared with non-endo-
metriotic controls. Thirteen eutopic (EuESCs) and nine ectopic (EESCs) endometrial 
stromal cells from endometriotic patients as well as eleven endometrial stromal cells 
from non-endometriotic controls (CESCs) were treated with resveratrol (100 μmol/L) 
or ethanol, and gene and/or protein expression of MCP-1, IL-6, IL-8 and RANTES 
was examined at 6, 24 and 48 hours following treatment in the cells from all origins. 
Resveratrol treatment significantly reduced gene and protein expression of MCP-1, 
IL-6, and IL-8 in EuESCs and EESCs compared with CESCs (P < .05-.001, P < .05-.001 
and P < .05-<.01, respectively), and this reduction was more noticeable in EESCs 
than EuESCs (P < .05-<.001). Besides, resveratrol treatment significantly reduced 
RANTES protein expression in EESCs in all time intervals (P < .05). Resveratrol treat-
ment significantly reduced the expression of MCP-1, IL-6, IL-8 and RANTES in EESCs.
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in the peritoneal microenvironment and chronic inflammation have 
crucial roles in endometriosis development6 as increased levels of 
pro-inflammatory cytokines and chemokines such as interleukin-6 
(IL-6), IL-8, monocyte chemotactic protein-1 (MCP-1), and regulated 
upon activation, normal T cell expressed and secreted (RANTES) 
have been detected in peritoneal fluid (PF) of endometriotic patients 
compared to non-endometriotic participants, suggesting that these 
secretory products may be involved in endometriosis initiation and 
progression through the promotion of growth, adhesion, invasion 
and proliferation of endometrial cells.7-9
Current treatment modalities for endometriosis are surgical and 
hormonal treatments, but the high incidence of disease recurrence 
and side effects of these therapies limit their usage in a long pe-
riod.10 Thus, in recent years, there has been an increasing emphasis 
on finding naturally occurring compounds for the management of 
endometriosis.
Resveratrol (trans-3,5,4′-trihydroxystilbene), a nutraceutical 
found in significant amounts in red grapes, berries, peanuts and red 
wine, is one of these substances.11 Protective effects of resveratrol 
on various diseases have been widely investigated in preclinical and 
clinical studies and attributed to anti-oxidative, anti-inflammatory, 
anti-tumorigenic, anti-atherogenic and anti-ageing properties of 
resveratrol.12
The first animal study of the effect of resveratrol on endometrio-
sis was reported by Bruner-Tran et al in 2011.13 In that study, resver-
atrol treatment decreased the number and volume of endometriotic 
lesions in a nude mouse model of endometriosis. In subsequent 
studies, resveratrol treatment in animal models of endometriosis de-
creased the number and size of endometriotic implants and showed 
anti-inflammatory, anti-angiogenic, anti-proliferative, anti-oxidative, 
and pro-apoptotic activities12 and in just one in vitro study resver-
atrol treatment showed anti-inflammatory effect through suppres-
sion of IL-8 expression in endometriotic stromal cells.14
So in this study, for the first time, we sought to investigate and 
compare the effect of resveratrol treatment on MCP-1, IL-6, and 
IL-8 gene expression and protein production and RANTES protein 
expression in ectopic and eutopic endometrial stromal cells of endo-
metriotic women (EESCs and EuESCs, respectively) and non-endo-
metriotic control endometrial stromal cells (CESCs).
2  | MATERIAL S AND METHODS
2.1 | Patient recruitment and tissue collection
This study included fifty-five patients admitted to gynaecology 
ward of Rassoul Akram hospital, who were allocated to two groups 
based on laparoscopy or hysterectomy findings: Group I (endome-
triosis group) consisted of forty women with stage III-IV peritoneal 
endometriosis, and group II (control group) consisted of fifteen 
women with benign gynaecological diseases and no evidence of 
endometriosis.
All women enrolled were at reproductive age (19-45 years old), 
with regular menstrual cycles, and were at the proliferative phase of 
the menstrual cycle. Those who had received hormonal treatment or 
antioxidant supplements within the last three months before sampling, 
or had the pelvic inflammatory disease, adenomyosis, malignancy, or 
were pregnant and breastfeeding were excluded. The diagnosis of en-
dometriosis was initially evaluated by an expert clinician during lap-
aroscopy and then confirmed by histopathological examination, and 
the severity of endometriosis was identified according to the revised 
American Society for Reproductive Medicine (rASRM).15 Before en-
rolling in the study, informed consent was obtained from each woman 
using protocols approved by the Human Ethics Committees of the Iran 
University of Medical Sciences (Code: IR.IUMS.REC.1395.28108).
Ectopic and eutopic endometrial samples were obtained through 
laparoscopic sampling and biopsy curette, respectively. Endometrial 
tissues were collected in sterile Falcon tubes containing Dulbecco's 
modified Eagle's medium (DMEM)-F12 (Gibco, Grand Island, NY, 
USA) and 1% penicillin-streptomycin antibiotics (Gibco, Grand 
Island, NY, USA) and immediately transported to the laboratory on 
ice, and a portion of tissue was sent to pathology for confirmation 
of endometriosis.
2.2 | Isolation, culture and purification of 
endometrial stromal cells (ESCs)
Isolation, culture and purification of ESCs described previously.16 
Briefly, fresh endometriotic tissue was minced to pieces of about 
1 mm3 and digested in DMEM-F12 containing 100 U/mL penicillin 
and 100 µg/mL streptomycin (Gibco, Grand Island, NY, USA), 2 mg/
mL of type I collagenase (Sigma-Aldrich, St Louis, MO, USA) and 
300 µg/mL of deoxynuclease I (Takara, Tokyo, Japan) for 120 minutes 
at 37°C, with intermittent vortexing every 15 minutes. After this pro-
cedure, the cell suspension was passed through 100-mm mesh (BD 
Biosciences, San Jose, CA, USA) to separate the cells from any re-
maining undigested tissues. The obtained single cells were transferred 
to T25 flasks and cultured under standard culturing conditions in 
DMEM-F12 supplemented with 10% fetal bovine serum (FBS) (Gibco, 
Grand Island, NY, USA) and 1% penicillin-streptomycin antibiotics 
(Gibco, Grand Island, NY, USA) in an incubator at 37°C in a humidified 
atmosphere with 5% CO2 for 24 hours. After this time, non-adherent 
cells were removed by gentle washing, leaving purified adherent ESCs 
to reach 80% confluence. Some samples were excluded from the 
study due to inconsistent pathology reports, culture contamination, 
or absence of enough cell growth, especially in the case of EESCs. 
Finally, thirteen eutopic and nine ectopic endometrial tissues from 
endometriotic patients and eleven eutopic endometrial tissues from 
non-endometriotic patients were used in this study. To confirm the 
purification of the ESCs, immunofluorescent staining and flow cytom-
etry analysis were used for the following antibodies: vimentin, nestin, 
cytokeratin, CD10, CD44, CD73, CD105, CD34 and CD45. Based on 
our findings, the ESCs of all three origins were pure.16
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2.3 | Determining the appropriate concentration for 
treatment of ESCs with resveratrol
In a pilot study, various concentrations of resveratrol (Sigma-
Aldrich) (12.5, 25, 50, 100, 200 and 400 µmol/L) were tested to 
find safety dose of resveratrol by MTT assay,17 based on MTT 
assay findings,16 four samples of EuESCs were treated with 25, 
50 and 100 µmol/L resveratrol and ethanol (vehicle) for 48 hours 
to determine appropriate treatment dose of resveratrol. For this 
purpose, the EuESCs were diluted with DMEM-F12 containing 
5% FBS to a seeding density of 16 × 104 cells/well and seeded 
into 24-well tissue culture plates (SPL Life Sciences, Korea) in a 
final volume of 1000 μL/well. After the cells were incubated for 
3 hours, the EuESCs were treated with varying concentrations 
(25, 50 and 100 μmol/L) of resveratrol or ethanol. After 1 hour, li-
popolysaccharide (LPS) (100 ng/mL) (Sigma-Aldrich, St Louis, MO, 
USA)18 was added, and cells were cultured for 48 hours. The su-
pernatant was then collected and stored at −40°C until assayed. 
The concentrations of IL-6 and IL-8 in the culture supernatants 
were determined in triplicate using commercially available IL-6 
and IL-8 ELISA kits (BD Bioscience, San Diego, CA, USA). Based 
on ELISA test results, concentrations of IL-6 and IL-8 were more 
decreased in the presence of 100 µmol/L resveratrol (data not 
shown). Besides, some previous studies showed anticarcino-
genic effects of resveratrol at doses 5 µmol/L and often close to 
100 µmol/L.19 So this concentration of resveratrol was used in 
subsequent treatments.
2.4 | Treatment of the ESCs with resveratrol
ESCs of three origins were seeded in 12-well plates (SPL Life 
Sciences, Korea) at a density of 32 × 104 cells/well and incubated 
for 3 hours. After 3 hours, ESCs were treated with 100 µmol/L res-
veratrol or ethanol, and 1 hour later, LPS (100 ng ⁄mL) (Sigma-Aldrich, 
St Louis, MO, USA)18,20 was added, and cells were cultured for 6, 24 
and 48 hours.
2.5 | RNA isolation, complementary DNA (cDNA) 
synthesis and quantitative real-time PCR (qRT-PCR)
Total RNA was isolated from ESCs using Trizol reagent (Qiagen, 
Germany) in accordance with the manufacturer's instructions. 
Concentration and purity of the extract were measured at an ab-
sorbance wavelength of 260/280 using a NanoDrop 2000 spec-
trophotometer (Thermo Fisher Scientific, Waltham, MA, USA), 
and the RNA integrity and quality were assessed by electrophore-
sis on 1% agarose gel. The concentrations of RNA samples ranged 
from 319.00 to 1244.7 ng/µL, and A260/280 ratio was greater 
than 1.8. After this step, equal amounts of RNA (1 µg) extracted 
from each sample was reverse transcribed into cDNA by Revert 
Aid First Strand cDNA Synthesis Kit (Thermo Fisher Scientific, 
Waltham, MA, USA) according to the manufacturer's protocols. 
The quantitative reverse-transcription polymerase chain reac-
tion was performed in duplicate using Rotor-Gene 3000 (Corbett 
Research, Sydney, Australia) with the syber premix Extaq (Biofact, 
Daejeon, Korea). The sequences of the primers, the size of am-
plicons and annealing temperature of each primer are shown in 
Table 1. A total reaction system of 20 μL contained syber premix 
Extaq (Biofact, Daejeon, Korea), 10 μL; primer pairs, 1 μL; cDNA 
template, 1 μL; and DNase-free water, 8 μL. Glyceraldehyde-3-
phosphate dehydrogenase (GADPH) was used as a housekeeping 
gene to normalize the amount of total RNA present in each reac-
tion. Thermocycler conditions included an initial holding at 95°C 
for 15 minutes, followed by 40 cycles of 95°C for 20 seconds, an-
nealing and elongation for 40 seconds and the melting step was 
from 60° to 99°C. Melting curve analyses were performed after 
amplification cycles to ensure the purity and specificity of the 
products. The efficiency of qRT-PCR reaction was determined 
by the standard curve, which was derived from serial dilutions 
of cDNA and qRT-PCR product in triplicate. The PCR amplifica-
tion efficiency of these candidate genes ranged from 95% to 97%, 
and the regression coefficient (R2 value) of the standard curve 
ranged from 0.968 to 0.998, well within the acceptable range of 
qRT-PCR.21
TA B L E  1   The quantitative real-time PCR primers used in this study





MCP-1 NM_002982.4 F: GAAAGTCTCTGCCGCCCTT 84 60
R: TTGATTGCATCTGGCTGAGCG
IL-6 NM_001371096 F: CTATGAACTCCTTCTCCACAAGCGCCTT 127 62
NM_000600.5 R: GGGGCGGCTACATCTTTGGAATCTT
IL-8 NM_000584.4 F: CTGCGCCAACACAGAAATTATTGTA 170 62
NM_001354840.2 R: TTCACTGGCATCTTCACTGATTCTT
GAPDH NM_002046.7 F: GCACCGTCAAGGCTGAGAAC 138 58
NM_001256799.3 R: TGGTGAAGACGCCAGTGGA
Abbreviations: bp, base pair; F, forward; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; IL-6, interleukin-6; IL-8, interleukin-8; MCP-1, 
monocyte chemotactic protein-1; R, reverse.
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2.6 | Measurement of MCP-1, IL-6, IL-8 and 
RANTES proteins
The concentration of the cytokines MCP-1, IL-6, IL-8 and RANTES 
in the supernatant of cultured ESCs was performed by ELISA, using 
commercially available kits (Duoset; R&D Systems, Minneapolis, MN, 
USA for MCP-1 and RANTES and BD Bioscience, San Diego, CA, USA 
for IL-6 and IL-8) in parallel and duplicate in accordance with the manu-
facturer's instructions. The minimum detection levels for MCP-1, IL-6, 
IL-8 and RANTES were 15.6, 4.7, 3.1 and 15.6 pg/mL, respectively.
F I G U R E  1   The basal expression 
levels of MCP-1 (A), IL-6 (B), IL-8 (C), 
and RANTES (D) genes and/or proteins 
in ESCs. Expression levels of MCP-1 
mRNA (Aa), MCP-1 protein (Ab), IL-6 
mRNA (Ba), IL-6 protein (Bb), IL-8 mRNA 
(Ca), IL-8 protein (Cb) and RANTES 
protein (Da) were measured in CESCs 
from non-endometriotic controls 
(n = 11), EuESCs (n = 13) and EESCs 
(n = 9) from endometriotic patients. 
Data were represented as mean ± SEM. 
Data from the basal protein expression 
were presented as box and whiskers 
graphs. *P < .05, **P < .01, ***P < .001, 
****P < .0001. CESCs, control endometrial 
stromal cells; EESCs, ectopic endometrial 
stromal cells; ESCs, endometrial stromal 
cells; EuESCs, eutopic endometrial stromal 
cells; MCP-1, monocyte chemotactic 
protein-1; RANTES, regulated upon 
activation, normal T cell expressed and 
secreted
F I G U R E  2   The effect of resveratrol treatment on MCP-1 gene and protein expression in ESCs. CESCs from non-endometriotic controls 
(n = 11), EuESCs (n = 13) and EESCs (n = 9) from endometriotic patients were cultured in the presence or absence of resveratrol for 6, 24 
and 48 hours. MCP-1 gene (A) and protein (B) expression at 6 (a), 24 (b) and 48 (c) hours after treatment were measured by quantitative real-
time PCR and enzyme-linked immunoassay, respectively. The differential effect of resveratrol treatment on ESCs from different groups was 
calculated as the ratio of the gene (C) and protein (D) expression of MCP-1 in the presence and absence of resveratrol at 6 (a), 24 (b) and 48 
(c) hours. Data were represented as mean ± SEM. Data from the protein expression were presented as box and whiskers graphs. *P < .05, 
**P < .01 and ***P ≤ .001. CESCs, control endometrial stromal cells; EESCs, ectopic endometrial stromal cells; ESCs, endometrial stromal 
cells; EuESCs, eutopic endometrial stromal cells; MCP-1, monocyte chemotactic protein-1
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2.7 | Statistical analysis
The statistical analysis of data was carried out using the GraphPad 
Prism software (version 6). The Kolmogorov-Smirnov test was used 
for the assessment of data normality. Based on the non-paramet-
ric distribution of data, Wilcoxon and Mann-Whitney U tests were 
used for comparison of variables within and between groups, re-
spectively. For the comparison of multiple groups, Kruskal-Wallis 
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test with Dunn post hoc analysis was used. The analysis of gene 
expression was performed comparing the fold change and relative 
expression by calculating the 2−ΔΔct and 2−Δct, respectively. Statistical 
significance was considered as P < .05.
3  | RESULTS
3.1 | The basal gene/protein expression levels of 
MCP-1, IL-6, IL-8 and RANTES in ESCs
Based on our findings, the basal gene and protein expression of 
MCP-1, IL-6 and IL-8 were significantly higher in EESCs compared 
with EuESCs and CESCs (P < .01-<.0001; P < .0001; and P < .05-
<.001, respectively). RANTES protein expression was also higher in 
EESCs compared with CESCs, but the difference was not significant 
(Figure 1).
3.2 | The effect of resveratrol treatment on MCP-1 
gene and protein expression in ESCs
As shown in Figure 2A, resveratrol treatment reduced MCP-1 gene 
expression in EESCs and EuESCs at 6, 24 and 48 hours (P < .05-
<.01) and in CESCs at 6 and 48 hours (P < .05). Regarding MCP-1 
protein expression, resveratrol treatment reduced MCP-1 protein 
expression in EESCs and EuESCs at 6, 24 and 48 hours (P < .05-
.001) and had no effect on CESCs (Figure 2B). The reducing ef-
fect of resveratrol treatment on MCP-1 gene expression was only 
significant in EESCs compared with EuESCs and CESCs in all time 
intervals (P < .05-<.01) (Figure 2C), and as shown in Figure 2D, the 
reducing effect of resveratrol treatment on MCP-1 protein expres-
sion was more remarkable in EESCs than EuESCs at 6 and 48 hours 
(P < .01).
3.3 | The effect of resveratrol treatment on IL-6 
gene and protein expression in ESCs
As shown in Figure 3A, resveratrol treatment reduced IL-6 gene 
expression in EESCs at 6, 24 and 48 hours (P < .05-<.01) and in 
EuESCs at 24 and 48 hours (P < .05) and had no effect on CESCs. 
Regarding IL-6 protein expression, resveratrol treatment reduced 
IL-6 protein expression in EESCs and EuESCs at 6, 24 and 48 hours 
(P < .05-.001) and had no significant effect on CESCs (Figure 3B). 
The effect of resveratrol treatment on IL-6 gene expression reduc-
tion was more significant in EESCs compared with EuESCs in all time 
intervals (P < .05-<.01; Figure 3C). However, the differential effect 
of resveratrol treatment on IL-6 protein expression reduction was 
not statistically significant between EuESCs and EESCs at 6, 24 and 
48 hours (Figure 3D).
3.4 | The effect of resveratrol treatment on IL-8 
gene and protein expression in ESCs
Resveratrol treatment reduced IL-8 gene expression in EESCs at 6, 
24 and 48 hours (P < .05-<.01) and in EuESCs at 6 and 24 hours 
(P < .05-<.01) and had no effect on CESCs (Figure 4A). Besides, 
resveratrol treatment reduced protein expression of IL-8 in EESCs, 
EuESCs and CESCs at 6, 24 and 48 hours (P < .05-<.01, Figure 4B). 
The effect of resveratrol treatment on IL-8 gene expression reduc-
tion was more significant in EESCs compared with EuESCs at all 
time intervals (P < .05-<.001, Figure 4C), although the differential 
effect of resveratrol treatment on IL-8 protein expression reduction 
was only significant at 48 hours in EESCs compared with EuESCs 
(P < .05, Figure 4D).
3.5 | The effect of resveratrol treatment on 
RANTES protein expression in ESCs
Resveratrol treatment reduced RANTES protein expression in 
EESCs at 6, 24 and 48 hours (P < .05) and had no effect on EuESCs 
and CESCs (Figure 5).
4  | DISCUSSION
We demonstrated in this study that EESCs express higher levels of 
MCP-1, IL-6 and IL-8 under basal conditions than EuESCs and CESCs. 
RANTES protein expression was also higher in EESCs than EuESCs 
and CESCs, but the difference was not significant. To the best of 
our knowledge, only one study compared the in vitro production 
of MCP-1 by ESCs in patients with and without endometriosis.22 
Consistent with our findings, in that study, EuESCs secreted more 
MCP-1 than CESCs. Regarding IL-6 and IL-8, our observations are 
well in accordance with previous studies that reported increased 
gene and/or protein expression of IL-623-25 and IL-823 in EESCs than 
EuESCs or CESCs. Regarding RANTES, previous studies also showed 
higher protein secretion by EESCs compared to CESCs.26,27
Sampson's theory (retrograde menstruation) is one of the most 
accredited hypotheses in explaining the pathophysiology of en-
dometriosis.4 As retrograde menstruation occurs in most cycling 
women, but only a minority develop endometriosis so additional 
factors like oxidative stress, inflammation and immunologic 
changes may contribute to the development of endometriosis.6 
Increased levels of reactive oxygen species (ROS) and pro-inflam-
matory cytokines in PF of endometriotic patients have been re-
ported in a number of studies.7,28 Excessive production of ROS as 
a result of iron overload as well as pro-inflammatory cytokines and 
LPS have been shown to activate the nuclear factor kappa B (NF-
κB) pathway, and NF-κB further increases transcription of mul-
tiple genes encoding pro-inflammatory cytokines, chemokines, 
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angiogenic, adhesion and growth factors that are known to be 
involved in development and progression of endometriosis.29 
Besides, constitutive activation of NF-κB has been demonstrated 
in endometriotic lesions and peritoneal macrophages of endome-
triotic patients compared to controls.30,31 So activation of NF-κB 
in endometriotic lesions may be an explanation for increased gene 
and protein expression of MCP-1, IL-6, IL-8 and RANTES in EESCs 
compared to EuESCs and CESCs.
MCP-1 and its receptor CCL2 have been shown to play a crucial 
role in the initiation and progression of endometriosis.32 MCP-1 is 
produced by many cell types, including macrophages, fibroblasts, 
endothelial and endometriotic stromal cells.33,34 and many studies 
have documented elevated levels of MCP-1 in the PF of patients 
with endometriosis.7
MCP-1 attracts monocytes and T lymphocytes.35,36 Moreover, 
MCP-1 has been demonstrated to increase apoptosis of T lym-
phocytes and not endometrial cells through an increase in Fas li-
gand (FasL) production in human ESCs.37 On the other hand, Li 
et al showed that expression of CCL2 in the EuESCs could enhance 
ESCs survival and invasion through activation of Akt and mito-
gen-activated protein kinase/ extracellular signal-regulated kinase 
1/2 (MAPK/Erk1/2) signalling pathway as anti-CCL2 neutralizing 
antibody or CCR2 antagonist can completely decrease these ef-
fects.38 Moreover, in our study, resveratrol treatment reduced gene 
and protein expression of MCP-1 in EESCs and EuESCs. However, 
this reduction was more pronounced in EESCs compared to EuESCs 
and CESCs. To the best of our knowledge, no study was investigated 
the effect of resveratrol treatment on MCP-1 gene and protein ex-
pression in ESCs but in only two studies resveratrol treatment in ex-
perimentally induced endometriosis rat model significantly reduced 
MCP-1 PF levels in treated groups compared to controls.39,40
IL-6 is one of the most prominent pro-inflammatory cytokines 
and angiogenic factors in endometriosis.41 It is strongly expressed 
by peritoneal macrophages42 and endometriotic lesions,43 and sig-
nificantly increased IL-6 levels have been reported in PF and en-
dometriotic lesions of patients with endometriosis compared to 
non-endometriotic controls.7,43 Besides, in line with our findings, 
other studies have indicated increased IL-6 production by EESCs 
than EuESCs or CESCs.23-25 IL-6 is a crucial mediator of cytokine cas-
cade in endometriosis.44 Besides, endometriotic stromal cell-derived 
IL-6 stimulates peritoneal macrophages towards M2-polarization. 
This type of macrophages plays an important role in inflammation 
and angiogenesis and causes ectopic endometrium to escape from 
apoptosis.45 So IL-6 might be one of the cytokines involved in the 
pathogenesis of endometriosis. So far, only one study investigated 
the effect of resveratrol treatment on plasma and PF levels of IL-6 
on an experimental rat model of endometriosis.46 Resveratrol treat-
ment in that study significantly reduced plasma and PF levels of IL-6 
compared to control.46 In our study for the first time, resveratrol 
treatment reduced gene and protein expression of IL-6 in EuESCs 
and EESCs and had no effect on CESCs.
IL-8 is a chemokine with potent neutrophil and T cell che-
motactic activities.47 Monocytes, macrophages,48 eutopic and 
ectopic endometrial stromal cells are principal sources of IL-8.23 
Inflammatory cytokines like IL-1, tumour necrosis factor-α (TNF-α) 
and LPS can also affect the release of this chemokine.49,50 Many 
studies have pointed to increased PF levels of IL-8 and its correla-
tion with disease stage.51 Besides consistent with our findings, 
other studies have shown increased IL-8 production by EESCs than 
EuESCs or CESCs.23 IL-8 may be involved in all processes related to 
the pathogenesis of endometriosis like adhesion, invasion, implan-
tation and proliferation of ectopic endometrial cells. Besides, it may 
protect ectopic endometrial cells from apoptosis through stimula-
tion of FasL apoptosis in activated T cells and inhibition of neutrophil 
apoptosis.52 Up to now, only one study investigated the effect of 
resveratrol treatment on plasma and PF levels of IL-8 on an endo-
metriosis rat model. Resveratrol treatment in that study significantly 
reduced plasma and PF levels of IL-8 compared to control.46 Besides, 
in a study by Taguchi et al, resveratrol treatment significantly sup-
pressed TNF-α -induced IL-8 release from the endometriotic stromal 
cells.14 In line with this finding, resveratrol treatment in our study 
significantly reduced gene and protein expression of IL-8 in EESCs.
RANTES is a potent chemotactic factor for monocytes and acti-
vated T cells.53 RANTES is produced by endometriotic stromal cells 
and peritoneal macrophages,54 and its concentrations are elevated 
in the peritoneal cavity of endometriotic patients and correlate 
with the disease severity.55 In our study, RANTES secreted more 
by EESCs and EuESCs compared to CESCs; however, the difference 
in secretion was not significant. In line with our findings, previous 
studies showed higher RANTES protein expression by EESCs and 
EuESCs compared to CESCs.26,27 RANTES can recruit inflammatory 
cells into the peritoneal cavity, and these cells, in turn, can release 
a variety of pro-inflammatory cytokines and angiogenic factors.56 
Besides, high levels of RANTES in the ectopic milieu can induce mac-
rophages tolerant, and this tolerant, in turn, not only inhibits apopto-
sis but also enhances the growth of ESCs.27 On the other hand, IL-1ß, 
as a predominant activated macrophage product, increases RANTES 
expression via NF-κB in endometriotic stromal cells.57
In our study, resveratrol treatment significantly reduced protein 
expression of RANTES in EESCs, and to the best of our knowledge, 
no study was investigated the effect of resveratrol treatment on 
RANTES protein expression in ESCs.
The mechanisms of resveratrol action related to reduced MCP-
1, IL-6, IL-8 and RANTES expression in EESCs are probably through 
regulation of pathways involved in oxidative stress, inflammation, 
cyclooxygenase (COX)-2 and Sirtuin 1 (Sirt1). Iron overload has 
been shown in different compartments of the peritoneal cavity of 
endometriotic patients and leads to the generation of ROS, which, 
along with a decrease in antioxidant defence in endometriotic pa-
tients result in oxidative stress.28 Oxidative stress also impairs cel-
lular functions through regulation of NF-κB,29 which is involved 
in endometriosis development. NF-κB activation stimulates the 
synthesis of pro-inflammatory cytokines (IL-6, IL-8, MCP-1 and 
RANTES), which are implicated in endometriotic cell proliferation, 
invasion and angiogenesis58 so inhibition of NF-κB activation may 
decrease the expression of these pro-inflammatory cytokines in 
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F I G U R E  3   The effect of resveratrol treatment on IL-6 gene and protein expression in ESCs. CESCs from non-endometriotic controls 
(n = 11), EuESCs (n = 13) and EESCs (n = 9) from endometriotic patients were cultured in the presence or absence of resveratrol for 6, 
24 and 48 hours. IL-6 gene (A) and protein (B) expression at 6 (a), 24 (b) and 48 (c) hours after treatment were measured by quantitative 
real-time PCR and enzyme-linked immunoassay, respectively. The differential effect of resveratrol treatment on EuESCs and EESCs was 
calculated as the ratio of the gene (C) and protein (D) expression of IL-6 in the presence and absence of resveratrol at 6 (a), 24 (b) and 48 
(c) hours. Data were represented as mean ± SEM. Data from the protein expression were presented as box and whiskers graphs. * P < .05, 
**P < .01 and *** P ≤ .001. CESCs, control endometrial stromal cells; EESCs, ectopic endometrial stromal cells; ESCs, endometrial stromal 
cells; EuESCs, eutopic endometrial stromal cells
     |  9KOLAHDOUZ-MOHAMMADI et AL.
F I G U R E  4   The effect of resveratrol treatment on IL-8 gene and protein expression in ESCs. CESCs from non-endometriotic controls 
(n = 11), EuESCs (n = 13) and EESCs (n = 9) from endometriotic patients were cultured in the presence or absence of resveratrol for 6, 24 
and 48 hours. IL-8 gene (A) and protein (B) expression at 6 (a), 24 (b) and 48 (c) hours after treatment were measured by quantitative real-
time PCR and enzyme-linked immunoassay, respectively. The differential effect of resveratrol treatment on ESCs from different groups was 
calculated as the ratio of the gene (C) and protein (D) expression of IL-8 in the presence and absence of resveratrol at 6 (a), 24 (b) and 48 
(c) hours. Data were represented as mean ± SEM. Data from the protein expression were presented as box and whiskers graphs. *P < .05, 
**P < .01 and ***P < .001. CESCs, control endometrial stromal cells; EESCs, ectopic endometrial stromal cells; ESCs, endometrial stromal 
cells; EuESCs, eutopic endometrial stromal cells
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endometriotic stromal cells. Resveratrol, as an antioxidant, has 
been shown to block NF-κB activation induced by ROS, TNF-
α, pro-inflammatory cytokines and LPS in several cell types.59,60 
On the other hand, elevated levels of TNF-α, IL-1ß, IL-6 and IL-8 
secreted by peritoneal macrophages and ectopic endometriotic 
lesions induce COX-2 expression and prostaglandins E2 (PGE2) 
production.61 Based on the literature, eutopic endometrium of 
endometriotic patients express more COX-2 than disease-free 
women, and COX-2 protein is highly expressed in ectopic than eu-
topic endometrium in endometriotic women.62 COX-2 inhibition in 
animal studies prevented the establishment and maintenance of 
endometriosis and decreased size and number of endometriotic 
tissues.63 Besides, studies have shown that increased COX-2 and 
COX-2 derived PGE2 production regulate survival, migration and 
invasion of endometriotic stromal cells in humans.62 Regarding 
resveratrol, Murias et al concluded that hydroxylated resvera-
trol analogues are selective COX-2 inhibitors.64 Besides, Sirt1, a 
mammalian homolog of silent information regulator 2 (Sir2), may 
be involved in endometriosis pathogenesis.65 Overexpression of 
Sirt1 was reported to suppress cytokines production and reduce 
inflammation in different animal models.66 Sirt1 inhibits NF-κB ac-
tivity and thereby inflammatory cytokine production.67 In a study 
by Taguchi et al, Sirt1 activation by resveratrol significantly sup-
pressed TNF-α-induced IL-8 release by endometriotic stromal cells 
and suppression of Sirt1 by sirtinol (an inhibitor of Sirt1) enhanced 
IL-8 secretion by endometriotic stromal cells.14
Therefore, in the light of present and previous findings, we can 
speculate that resveratrol as a natural and safe treatment may slow 
down the development of endometriosis and ameliorate its mani-
festations through its pleiotropic properties. However, as adhe-
sion molecules, extracellular matrix metalloproteinase and other 
pro-inflammatory cytokines activate/alter peritoneal microenvi-
ronment and epigenetic as well as genetic mechanisms have role in 
endometriosis pathogenesis, future studies should aim to clarify the 
effect of resveratrol on these factors.68,69
5  | CONCLUSION
Our results showed that EESCs differed significantly from EuESCs 
and CESCs concerning MCP-1, IL-6, IL-8, and RANTES gene and/or 
protein expression. Besides, resveratrol treatment in this study sig-
nificantly reduced the expression of MCP-1, IL-6, IL-8 and RANTES 
in EESCs. Based on the results presented here and beneficial effects 
of resveratrol treatment in animal models of endometriosis, fur-
ther in vivo and randomized controlled trials are recommended to 
achieve more conclusive results about the efficacy of resveratrol in 
endometriosis treatment.
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